ArticleSchizophrenia research2015
Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.
Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.Schizophrenia research · 2018Pooled it
- A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression.Biological psychiatry · 2016Pooled it
- Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Central auditory processing deficits in schizophrenia: Effects of auditory-based cognitive training.Schizophrenia research · 2021Trial
- CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.Psychopharmacology · 2020Trial
- Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients.Schizophrenia research · 2020Trial
- Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Neurophysiological Effects of Bitopertin in Schizophrenia.Journal of clinical psychopharmacology · 2017Trial
- Strong connections of locally clustered neurons in the upper-layer cortex underlie schizophrenia-related auditory deviance detection.Science advances · 2026Article
- Visual P300 and Risk for Psychosis Onset in Youth at Clinical High Risk.Biological psychiatry · 2026Article
- Investigating neural impairments in psychotic disorders using electroencephalography and cortical spheroids.Translational psychiatry · 2026Article
- Protein-protein interaction-interfering peptide rescues dysregulated NMDA receptor signaling.JCI insight · 2026Article
- Localizing hierarchical prediction errors and precisions during an oddball task with volatility: Computational insights and relationship with psychosocial functioning in healthy individuals.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Intraindividual Variability of Event-Related Potentials in Psychosis: A Registered Report.Biological psychiatry global open science · 2025Article
- Features of mismatch negativity in an at-risk mental state with the traits associated with the autistic spectrum.Frontiers in psychiatry · 2025Article
- Clarifying directional dependence among measures of early auditory processing and cognition in schizophrenia: leveraging Gaussian graphical models and Bayesian networks.Psychological medicine · 2024Article
- Psychosis superspectrum II: neurobiology, treatment, and implications.Molecular psychiatry · 2024Review
- P300 in schizophrenia: Then and now.Biological psychology · 2024Review
- Neural Circuitry-Related Biomarkers for Drug Development in Psychiatry: An Industry Perspective.Advances in neurobiology · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test-retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study. The extent to which demographic, clinical, cognitive, and functional characteristics contribute to variability in MMN and P3a amplitudes was also examined. Participants (HCS n=824, SZ n=966) underwent testing at 5 geographically distributed COGS laboratories. Valid ERP recordings were obtained from 91% of HCS and 91% of SZ patients. Highly significant MMN (d=0.96) and P3a (d=0.93) amplitude reductions were observed in SZ patients, comparable in magnitude to those observed in single-lab studies with no appreciable differences across laboratories. Demographic characteristics accounted for 26% and 18% of the variance in MMN and P3a amplitudes, respectively. Significant relationships were observed among demographically-adjusted MMN and P3a measures and medication status as well as several clinical, cognitive, and functional characteristics of the SZ patients. This study demonstrates that MMN and P3a ERP biomarkers can be feasibly used in multi-site clinical studies. As with many clinical tests of brain function, demographic factors contribute to MMN and P3a amplitudes and should be carefully considered in future biomarker-informed clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.